Patents by Inventor Yibin Zeng

Yibin Zeng has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Diaryl substituted 6,5-fused ring compounds as C5aR inhibitors
    Patent number: 11478460
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: October 25, 2022
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • 5-5 fused rings as C5a inhibitors
    Patent number: 11479553
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: May 4, 2020
    Date of Patent: October 25, 2022
    Assignee: CHEMOCENTRYX, INC.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Yibin Zeng, Penglie Zhang
  • Heteroaryl sulfonamides and CCR2/CCR9
    Patent number: 11433061
    Abstract: Compounds are provided that act as potent antagonists of the CCR2 receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR2. The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR2-mediated diseases, and as controls in assays for the identification of CCR2 antagonists.
    Type: Grant
    Filed: January 10, 2020
    Date of Patent: September 6, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Solomon Ungashe, Zheng Wei, Arindrajit Basak, Trevor T. Charvat, Wei Chen, Jeff Jin, Jimmie Moore, Yibin Zeng, Sreenivas Punna, Daniel Dairaghi, Derek Hansen, Andrew M. K. Pennell, John J. Wright, Antoni Krasinski, Qiang Wang
  • Salt forms of a complement component C5A receptor
    Patent number: 11427541
    Abstract: Provided herein are salt forms of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the salt forms of Compound 1, described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: August 30, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Rajinder Singh, Kwok Yau, Yibin Zeng, Penglie Zhang, Rebecca M. Lui, Ju Yang, Howard S. Roth
  • 6-5 fused rings as C5a inhibitors
    Patent number: 11384079
    Abstract: The present disclosure provides, inter alia, Compounds of Formula (I) or pharmaceutically acceptable salts thereof that are modulators of the C5a receptor. Also provided are pharmaceutical compositions and methods of use including the treatment of diseases or disorders involving pathologic activation from C5a and non-pharmaceutical applications.
    Type: Grant
    Filed: December 20, 2019
    Date of Patent: July 12, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Christopher W. Lange, Rebecca M. Lui, Viengkham Malathong, Venkat Reddy Mali, Sreenivas Punna, Rajinder Singh, Hiroko Tanaka, Yibin Zeng, Penglie Zhang
  • SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS
    Publication number: 20220153733
    Abstract: Compounds are provided that are modulators of the CCR2 receptor. The compounds have the general formula (Ia1?): and are useful in pharmaceutical compositions, methods or the treatment of diseases and disorders involving the pathologic activation of CCR2 receptors.
    Type: Application
    Filed: June 24, 2021
    Publication date: May 19, 2022
    Inventors: Junfa FAN, Jaroslaw KALISIAK, Rebecca M. LUI, Venkat Reddy MALI, Jeffrey P. McMAHON, Jay P. POWERS, Hiroko TANAKA, Yibin ZENG, Penglie ZHANG
  • CXCR7 ANTAGONISTS
    Publication number: 20220127272
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Application
    Filed: May 27, 2021
    Publication date: April 28, 2022
    Inventors: Junfa FAN, Antoni KRASINSKI, Christopher W. LANGE, Rebecca M. LUI, Jeffrey P. McMAHON, Jay P. POWERS, Yibin ZENG, Penglie ZHANG
  • FREE BASE CRYSTALLINE FORM OF A COMPLEMENT COMPONENT C5a RECEPTOR
    Publication number: 20220096453
    Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.
    Type: Application
    Filed: May 4, 2021
    Publication date: March 31, 2022
    Inventors: Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Antoni KRASINSKI
  • Triaryl compounds for treatment of PD-L1 diseases
    Patent number: 11266643
    Abstract: Compounds are provided that are useful as immunomodulators. The compounds have the Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1a, R1b, R1c, R1d, R2a, R2b, R3, R3a, R4, R6, R7, R8, A, Z, X1 and n are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: May 14, 2020
    Date of Patent: March 8, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Christopher Lange, Venkat Reddy Mali, Darren J. McMurtrie, Viengkham Malathong, Sreenivas Punna, Rajinder Singh, Ju Yang, Yibin Zeng, Penglie Zhang
  • Soluble C5aR antagonists
    Patent number: 11254695
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Grant
    Filed: October 23, 2019
    Date of Patent: February 22, 2022
    Assignee: ChemoCentryx, Inc.
    Inventors: Pingchen Fan, Antoni Krasinski, Venkat Reddy Mali, Shichang Miao, Sreenivas Punna, Yang Song, Valentino J. Stella, Yibin Zeng, Penglie Zhang
  • AZA-ARYL 1H-PYRAZOL-1-YL BENZENE SULFONAMIDES
    Publication number: 20220047575
    Abstract: Compounds are provided that act as potent antagonists of the CCR(9) receptor. Animal testing demonstrates that these compounds are useful for treating inflammation, a hallmark disease for CCR(9). The compounds are generally aryl sulfonamide derivatives and are useful in pharmaceutical compositions, methods for the treatment of CCR(9)-mediated diseases, and as controls in assays for the identification of CCR(9) antagonists.
    Type: Application
    Filed: October 29, 2021
    Publication date: February 17, 2022
    Inventors: Xi CHEN, Junfa FAN, Pingchen FAN, Antoni KRASINSKI, Lianfa LI, Rebecca M. LUI, Jeffrey P. McMAHON, Jay P. POWERS, Yibin ZENG, Penglie ZHANG
  • METHODS OF TREATING CANCER USING HETEROARYL-BIPHENYL AMIDE DERIVATIVES
    Publication number: 20210393759
    Abstract: Provided herein are methods of treating certain cancers comprising administering to the subject in need there of an effective amount of a compound of Formula (I) including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2, R3, R4, Ra, and Rb are as defined herein.
    Type: Application
    Filed: June 22, 2021
    Publication date: December 23, 2021
    Inventors: Shijie LI, Marta VILALTA-COLOMER, Yibin ZENG, Penglie ZHANG
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING A COMBINATION THERAPY OF SMALL MOLECULE INHIBITORS OF C-C CHEMOKINE RECEPTOR TYPE 9 (CCR9) AND ANTI-ALPHA4BETA7 INTEGRIN BLOCKING ANTIBODIES
    Publication number: 20210322410
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Application
    Filed: May 24, 2021
    Publication date: October 21, 2021
    Inventors: James CAMPBELL, Israel CHARO, Thomas SCHALL, Karen EBSWORTH, Yu WANG, Yibin ZENG, Penglie ZHANG, Joanne TAN
  • COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY BOWEL DISEASE USING CCR9 INHIBITOR AND ANTI-IL-23 BLOCKING ANTIBODIES
    Publication number: 20210308119
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-IL-23 antibody. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-IL-23 antibody.
    Type: Application
    Filed: March 31, 2021
    Publication date: October 7, 2021
    Inventors: James CAMPBELL, Israel CHARO, Thomas SCHALL, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
  • DEUTERATED COMPOUNDS AS IMMUNOMODULATORS
    Publication number: 20210276955
    Abstract: Compounds are provided to modulate the C5a receptor. The compounds have the following Formula (I): including stereoisomers and pharmaceutically acceptable salts thereof, wherein R1, R2 and R3 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
    Type: Application
    Filed: October 9, 2020
    Publication date: September 9, 2021
    Inventors: Pingchen FAN, Rebecca M. LUI, Venkat Reddy MALI, Rajinder SINGH, Yibin ZENG, Penglie ZHANG
  • C5AR ANTAGONISTS
    Publication number: 20210269398
    Abstract: Compounds are provided that are modulators of the C5a receptor. The compounds are substituted piperidines and are useful in pharmaceutical compositions, methods for the treatment of diseases and disorders involving the pathologic activation of C5a receptors.
    Type: Application
    Filed: October 20, 2020
    Publication date: September 2, 2021
    Inventors: Pingchen Fan, Kevin Lloyd Greenman, Manmohan Reddy Leleti, Yandong Li, Jay Powers, Hiroko Tanaka, Ju Yang, Yibin Zeng
  • CXCR7 antagonists
    Patent number: 11059825
    Abstract: Compounds having formula I, or pharmaceutically acceptable salts, hydrates or N-oxides thereof are provided and are useful for binding to CXCR7, and treating diseases that are dependent, at least in part, on CXCR7 activity. Accordingly, the present invention provides in further aspects, compositions containing one or more of the above-noted compounds in admixture with a pharmaceutically acceptable excipient.
    Type: Grant
    Filed: April 9, 2019
    Date of Patent: July 13, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Junfa Fan, Antoni Krasinski, Christopher W. Lange, Rebecca M. Lui, Jeffrey P. McMahon, Jay P. Powers, Yibin Zeng, Penglie Zhang
  • Free base crystalline form of a complement component C5a receptor
    Patent number: 11026935
    Abstract: Provided herein is a free base crystalline form of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the crystalline free base form of Compound 1 described herein.
    Type: Grant
    Filed: November 6, 2020
    Date of Patent: June 8, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Rajinder Singh, Kwok Yau, Yibin Zeng, Penglie Zhang, Rebecca M. Lui, Antoni Krasinski
  • Compositions and methods for treating inflammatory bowel disease using a combination therapy of small molecule inhibitors of C—C chemokine receptor type 9 (CCR9) and anti-?4?7 integrin blocking antibodies
    Patent number: 11020394
    Abstract: Provided herein are compositions, methods and kits for treating inflammatory bowel disease (IBD) such as Crohn's disease and ulcerative colitis in a mammal in need thereof. The method include administering to a subject with IBD a combination therapy containing a therapeutically effective amount of a chemokine receptor 9 (CCR9) inhibitor compound and a therapeutically effective amount of an anti-?4?7 integrin antibody such as vedolizumab. Also provided herein is a kit containing the CCR9 inhibitor compound and anti-?4?7 integrin antibody.
    Type: Grant
    Filed: December 9, 2019
    Date of Patent: June 1, 2021
    Assignee: ChemoCentryx, Inc.
    Inventors: Yibin Zeng, Penglie Zhang, Thomas Schall, Israel Charo, James J. Campbell
  • SALT FORMS OF A COMPLEMENT COMPONENT C5A RECEPTOR
    Publication number: 20210139427
    Abstract: Provided herein are salt forms of a complement component 5a receptor having the formula of Compound 1 Also provided herein are pharmaceutical compositions and methods of treatment using the salt forms of Compound 1, described herein.
    Type: Application
    Filed: November 6, 2020
    Publication date: May 13, 2021
    Inventors: Rajinder SINGH, Kwok YAU, Yibin ZENG, Penglie ZHANG, Rebecca M. LUI, Ju YANG, Howard S. ROTH